Mereo BioPharma Group Plc
(NASDAQ : MREO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -4.14%75.210.0%$2384.51m
NVAXNovavax, Inc. 9.47%172.0699.2%$1277.52m
GILDGilead Sciences, Inc. -2.41%69.171.0%$527.06m
AMGNAmgen, Inc. -1.02%241.121.3%$510.39m
REGNRegeneron Pharmaceuticals, Inc. -2.27%633.692.5%$464.78m
SRNESorrento Therapeutics, Inc. 4.67%13.441.8%$436.74m
BNTXBioNTech SE -2.54%81.060.0%$402.40m
VRTXVertex Pharmaceuticals, Inc. -1.52%271.521.9%$378.73m
VXRTVaxart, Inc. 10.29%9.810.0%$330.19m
ILMNIllumina, Inc. 2.14%402.113.5%$326.79m
BIIBBiogen, Inc. -0.12%275.751.6%$326.53m
IBIOiBio, Inc. 1.34%4.451.8%$185.13m
EBSEmergent BioSolutions, Inc. 8.34%132.866.4%$175.32m
SGENSeattle Genetics, Inc. -1.15%163.186.1%$173.10m
ALXNAlexion Pharmaceuticals, Inc. -2.41%102.682.0%$170.74m

Company Profile

Mereo BioPharma Group Plc engages in the acquisition, development, and commercialization of therapeutics that aim to improve outcomes for patients with rare and specialty diseases. It focuses on the treatment of patients with osteogenesis imperfecta, alpha-1 antitrypsin deficiency, hypogonadotropic hypogonadism in obese men, and acute exacerbations of chronic obstructive pulmonary disease. The company was founded by Denise Vera Pollard-Knight, Charles Sermon, Alastair MacKinnon, and John Richard in March 2015 and is headquartered in London, the United Kingdom.